Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
If society is to remain in step with new technology, the scientific community needs to be better educated about the social and ethical implications of its research.
A billion nonredundant molecular interactions lie buried in the biomedical literature. A text-mining approach could help scientists better exploit this knowledge.
Academic ownership of intellectual property facilitated wide dissemination and commercialization of antibody technology. Moves at the University of Cambridge to reclaim institutional IP rights should thus be treated with caution.
In responding to future influenza pandemics and other infectious agents, plasmid DNA overcomes many of the limitations of conventional vaccine production approaches.
At the end of next month, the European Medicines Agency (EMEA) will implement a new legislative framework and several provisions that seek to provide incentives and streamline regulatory oversight of certain monoclonal antibodies and other biologic products.
Ensuring adequate manufacturing capacity for recombinant and monoclonal antibodies is one of the greatest challenges facing the biotech industry. The following factors should be taken into account when designing product development and production strategies.
The failure of many bio-ontologies to follow international standards for ontology design and description is hampering their application and threatens to restrict their future use.
The current legal system fails to provide an equitable balance between the rights of researchers and the rights of donors of biological materials. Could the tax system provide a solution?
A lack of proven commercial success and a surfeit of ethical, legal and political problems make stem cell companies a difficult pitch to venture capitalists.
Responding to a lack of US government leadership on the conduct of human embryonic stem cell research, a National Academies panel has proposed the creation of new institutional oversight committees.
New rules to assess the safety and efficacy of human cell- and tissue-based products are the culmination of a multiyear, cooperative effort between the US government and the biotech industry.
The Standard Metabolic Reporting Structures (SMRS) working group outlines its vision for an open,community-driven specification for the standardization and reporting of metabolic studies.
The US Supreme Court is considering the reach of patents into basic research. If it decides to exempt a broad swathe of research, the biotech industry could lose millions.